Greenberg Traurig, LLP Shareholder Andrew B. Schwaab will present the Silicon Valley Intellectual Property Law Association’s (SVIPLA) annual 2020 Inventor of the Year award to prolific inventor and technologist,
Continue Reading Greenberg Traurig Congratulates Robert Cousins, Named 2020 Inventor of the Year
David J. Dykeman and Bethany A. Stokes co-authored a Medical Design & Outsourcing article titled “5 Keys to Stronger Medtech Agreements.”
Read the full article, “5 Keys to Stronger
From floating infrastructure to biohacking, floating solar farms to AgTech, projects that are first of their kind bring with them exciting opportunities, but also unique legal complexities. In this recent
Continue Reading Maneuvering ‘Unicorns’ – Opportunities and Risks of Unprecedented Projects
The search for a vaccine for the COVID-19 strain of coronavirus has put the spotlight once again on the innovative pharmaceuticals sector. As pharmaceutical companies and innovators across the globe work diligently on a vaccine, many of these companies may be looking to protect their innovation. While patents have many benefits, in the face of a global health emergency, there are some key factors innovators should consider.
Timeline for Patent Registration
Patents can provide broad protection for invention and innovation. They can also create a significant advantage in the marketplace. However, patent registration takes time and may require significant resources. According to the United States Patent and Trademark Office (USPTO), on average, it takes approximately 22 months to get patent approval. This period may be shortened by taking advantage of one of the USPTO’s accelerated examination procedures and may be shortened by utilizing the USPTO prioritized examination option, where a final decision on patentability is made within 12 months from the filing date of the patent application.
Continue Reading The Race for a COVID-19 Vaccine is On: Key Factors May Impact Patent Protection
On April 28, 2020, the United States Patent and Trademark Office (USPTO) announced a new extension of certain submissions and fees under the Coronavirus Aid, Relief, and Economic Security Act
Continue Reading USPTO Announces Extensions Under CARES Act
On March 28, 2020, President Trump signed into law a historic $2.2 trillion stimulus package, namely, the Coronavirus Aid, Relief, and Economic Security (CARES) Act, in response to the novel
Continue Reading CARES Act Considerations for Emerging Tech Companies
On March 31, 2020, the United States Patent and Trademark Office (USPTO) announced extension of certain submissions and fees under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
Continue Reading USPTO Announces Possible Extensions Under CARES Act
Most of us know that DATA, the beloved android from Star Trek, The Next Generation, is an artificial intelligence (AI) life form from the distant future with a high capacity to problem solve and innovate. But, if DATA were present today and invented a new technology, could he be an inventor on a patent for his invention?
The question of whether AI can legally be an inventor on a patent was recently addressed by the European Patent Office (EPO) and The United Kingdom Intellectual Property Office (UKIPO). The same question is still being evaluated by U.S. Patent and Trademark Office (USPTO) along with solicitation for comments to the patent community.
Continue Reading Could Star Trek’s DATA Be a Patent Inventor?
On Dec. 19, 2019, the Original Grant Patent (OGP) system will launch in Hong Kong Special Administrative Region (SAR). This new system will provide patent applicants an alternate path for
Continue Reading Hong Kong Original Grant Patent (OGP) System to Launch Dec. 19